
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc. demonstrated significant growth in genomic test volume, increasing by 25% to a total of 39,107 tests, bolstered by a substantial 45% rise in urology tests from its Decipher platform. The company also saw a notable improvement in financial performance, with adjusted EBITDA margin advancing by 690 basis points year-over-year and testing revenue reaching $112.2 million, marking a 24% increase in the fourth quarter. Additionally, management projects continued improvement in adjusted EBITDA margins for 2025, alongside strong potential drivers from expanding sales of existing tests and improved operational cash flow.
Bears say
Veracyte Inc. faces a negative outlook primarily due to slowing revenue growth, with an anticipated growth rate of only 10-15%, primarily attributed to underperforming Afirma and Decipher tests. Despite a reduction in selling, general and administrative expenses, as well as improvements in non-GAAP operating and adjusted EBITDA margins, the overall testing revenue growth decelerated from 29% in 3Q24 to 21% in 4Q24, indicating potential market challenges. Additionally, uncertainty surrounding the potential exit from the VCYT subsidiary could further dampen consensus revenue expectations for 2025, leading to concerns about the company's long-term financial stability.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares